Viral particles support prophylactic vaccination against breast cancer
Mimotopes applied in vaccinations of cancer patients can trigger long-term immune response. For a vaccine, however, an immune-reactive carrier is required. Researchers from the Messerli Research Institute at Vetmeduni Vienna thus produced mimotopes for HER2, a tumour antigen of about 30 percent of breast tumours, at virus-like particles of harmless adeno-associated viruses (AAV) without chemical after-treatment and used them directly as a specific vaccine. This vaccine could serve as a prophylaxis for high-risk patients or breast cancer patients that after therapy. Treatment of canine breast tumours likewise seems possible. The results were published in OncoImmunology and Oncology Letters. (Mehr in: Pressemitteilungen – idw – Informationsdienst Wissenschaft)
Comments are closed.